A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

The current AI drug development “toolkit” For ease of ... it is a balance of factors, like the maturity of the field and the predictability of the relevant feature. Patent law jurisprudence ...

“Most enterprises fixated on AI ROI will scale back prematurely,” the research ... Organizations have different levels of AI maturity. Facing an endless array of new AI-powered technologies ...

Learn More Pharmaceutical giant GSK is pushing the boundaries of what generative AI can achieve in healthcare areas like scientific literature review, genomic analysis and drug discovery.

drug discovery, development, manufacturing, and quality control. This collaboration combines the power of Microsoft’s secure Azure platform with the Tetra Scientific Data and AI Cloud ™ to ...

When Genentech licensed experimental drug ... large-scale experiments and we use these experiments in order to understand the biology.'" Executives and industry experts caution that AI adoption ...